| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| Biex, Inc. |
| 6693 Sierra Lane, Suite F, Dublin, CA 94568 * (925) 556-0300 |
| The company is a women's health care company focused on developing and marketing innovative solutions for maternity management. |
| Manager | Tier | Phone |
| Nationsbanc Montgomery Securities, Inc. | Lead Manager | (415) 627-2100 |
| Salomon Smith Barney | Co-manager | (212) 723-7300 |
| Wessels, Arnold & Henderson | Co-manager | (612) 373-6105 |
| NASNTL: | BIEX | Manufacturing: | SIC 3829 | |
| Type of Shares: | Common Shares | Filing Date: | 3/16/98 | |
| U.S. Shares Filed: | 0 | Filing Price: | - | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $42,500,000 | |
| Primary Shares: | 0 | Expenses: | $575,000 | |
| Secondary Shares: | 0 | Post-IPO Shares: | ||
| Employees: | 28 |
| Issuer's Law Firm: | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm: | Wilson, Sonsini, Goodrich & Rosati |
| Registrar/Transfer Agent: | BankBoston |
| Auditor: | Arthur Andersen |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/97 | 12/31/97 | ||||
| Revenue: | $0.00 | Assets: | $8.50 | ||
| Net Income: | -$3.84 | Curr Assets: | $8.37 | ||
| EPS: | -$0.35 | Liabilities: | $1.47 | ||
| Prior EPS: | -$0.48 | Curr Liab: | $1.47 | ||
| Cash Flow/Oper: | -$3.70 | Equity: | $7.03 | ||
| Cash Flow/Fin: | $10.55 | Cash: | $0.19 | ||
| Cash Flow/Inv: | -$7.10 | Working Cap: | $6.90 | ||
| Competition |
| The Company competes with providers of traditional and other methods for screening for the risk of spontaneous preterm labor and delivery. Several health care organizations have developed commercially available risk screening and management programs for preterm labor and delivery, most of which use the traditional method of risk identification. Other approaches for screening for the risk of spontaneous preterm labor and delivery are in various stages of development and market acceptance. Currently, Adeza Biomedical Corporation ("Adeza") markets the only FDA-approved immunodiagnostic test for the assessment of likelihood of preterm delivery. Adeza's fetal fibronectin immuno assay was approved for marketing as a diagnostic aid for symptomatic patients in 1995 and in January 1997, it was approved for the screening of asymptomatic patients to detect the risk of preterm delivery at less than 34 completed weeks of gestation. Recently, vaginally inserted ultrasound probes have been used to assess cervical length and dilation and as a tool for determining the risk of spontaneous preterm labor and delivery. Additionally, various biological markers are being studied as early markers of spontaneous preterm labor and delivery. |
| Business Plan |
| Biex is a women's health care company focused on developing and marketing innovative solutions for maternity management. The Company is focused on establishing the SalEst system as a routine method of aiding in the identification of women who are at risk of spontaneous preterm labor and delivery. Key elements of the Company's strategy are: (I) Launch the Salest System, (ii) Establish Reimbursement, (iii) Build Proprietary Clinical Database, (iv) Leverage Core Technology and (v) Establish International Presence Through Strategic Parnters. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to develop sales, marketing and distribution capabilities, expand research and development, expand clinical trials and provide working capital and for general corporate purposes. |